Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY 288513

Known as: LY288513 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
This study investigated the behavioral mechanisms underlying the anxiogenic, or anxiolytic mediated effects of CCK(2) receptor… Expand
Is this relevant?
1998
1998
Defensive rage behavior is mediated over a descending pathway from the medial hypothalamus to the dorsolateral midbrain… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
SummaryCholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in the highest levels in… Expand
  • table I
  • table II
Is this relevant?
1997
1997
Pre-pulse inhibition (PPI) of the acoustic startle response is the diminution of the startle response when the startle stimulus… Expand
Is this relevant?
1996
1996
The activity of LY288513, an investigational cholecystokinin (CCK)B antagonist, was evaluated in a wide range of pharmacological… Expand
Is this relevant?
1996
1996
The potency and specificity of five proposed cholecystokinin-B receptor antagonists, YM022, RP73870, L-740,093, L-365,260 and… Expand
Is this relevant?
1996
1996
IN order to explore the potential clinical utility of CCK-B antagonists for the treatment of nicotine withdrawal symptoms, the… Expand
Is this relevant?
1996
1996
In order to investigate the involvement of cholecystokinin (CCK) in the regulation of anxiety, the effect of the selective non… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
The diphenylpyrazolidinone cholecystokinin (CCK)-B antagonist LY262691 has recently been demonstrated to decrease the number of… Expand
Is this relevant?
1993
1993
In order to explore the potential clinical utility of CCK-B antagonists for the treatment of benzodiazepine withdrawal symptoms… Expand
Is this relevant?